Immunome, Inc. (IMNM) Stock Price & How to Invest

Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates.

As a pre-commercial developer, Immunome generates only minimal collaboration-related revenue (roughly $7 million in 2025) against large research spending and recurring net losses, so the investment picture is not about earnings today. It is about whether varegacestat wins approval and launches successfully into a market where a rival oral therapy already exists, and whether the broader ADC engine produces additional clinical wins. A cash position of roughly $582.7 million as of March 2026 funds that plan into 2028, but the equity remains a speculative, catalyst-driven biotech.

As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Immunome, Inc.'s investor relations page or your broker.

• Market cap: ~$2.6B
• Share price: ~$23
• Revenue (FY2025): ~$7M
• Cash & equivalents (Mar 2026): ~$582.7M
• Net loss (Q1 2026): ~$53.8M
• R&D expense (Q1 2026): ~$46.4M

Immunome trades on pipeline expectations, not profits, so conventional earnings multiples do not apply to a pre-commercial developer with minimal revenue and ongoing losses. Its roughly $2.6 billion market value largely reflects the market's probability-weighted view of varegacestat approval plus the ADC pipeline. The sizable cash balance funds operations into 2028 but does not by itself justify the valuation.

There are three common ways to get IMNM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IMNM sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where IMNM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

IMNM is a well-funded, pre-commercial cancer-drug developer whose value rides on varegacestat clearing the FDA and its ADC pipeline maturing, which makes it high-risk and event-driven rather than a cash-flow story.

Whether IMNM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IMNM a buy?, and where the stock could go from here in the IMNM stock forecast.

For income investors, whether IMNM pays a dividend and how the payout looks is covered in does IMNM pay a dividend?